Strain-dependent variation in Mycobacterium bovis BCG-induced human T-cell activation and gamma interferon production in vitro

Infection and Immunity

Volumn 75, Issue 6, 2007, Pages 3197-3201

  Aguirre Blanco, Ana M ^a,c   Lukey, Pauline T ^b   Cliff, Jacqueline M ^a   Dockrell, Hazel M ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2 RECEPTOR ALPHA;

ARTICLE; BACTERIAL STRAIN; BCG VACCINATION; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; INTERFERON PRODUCTION; MYCOBACTERIUM BOVIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANTIBODIES, BACTERIAL; BCG VACCINE; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MYCOBACTERIUM BOVIS; T-LYMPHOCYTES;

EID: 34249900172     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.01611-06     Document Type: Article

References (25)

1. Abou-Zeid, C., I. Smith, J. Grange, J. Steele, and G. Rook. 1986. Subdivision of daughter strains of bacille Calmette-Guerin (BCG) according to secreted protein patterns. J. Gen. Microbiol. 132:3047-3053.
2. Bedwell, J., S. K. Kairo, M. A. Behr, and J. A. Bygraves. 2001. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine 19:2146-2151.
3. Behr, M. A. 2002. BCG - different strains, different vaccines? Lancet Infect. Dis. 180:141-149.
4. Behr, M. A., and P. M. Small. 1997. Has BCG attenuated to impotence? Nature 389:133-134.
5. Behr, M. A., and P. M. Small. 1999. A historical and molecular phylogeny of BCG strains. Vaccine 17:915-922.
6. Behr, M. A., M. A. Wilson, W. P. Gill, H. Salamon, G. K. Schoolnik, S. Rane, and P. M. Small. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520-1523.
7. Brewer, T. F. 2000. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin. Infect. Dis. 31(Suppl. 3):S64-S67.
8. Canaday, D. H., C. Ziebold, E. H. Noss, K. A. Chervenak, C. V. Harding, and W. H. Boom. 1999. Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway. J. Immunol. 162:372-379.
9. Collins, F. M. 1985. Protection to mice afforded by BCG vaccines against an aerogenic challenge by three mycobacteria of decreasing virulence. Tubercle 66:267-276.
10. Esin, S., G. Batoni, G. Kallenius, H. Gaines, M. Campa, S. B. Svenson, R. Andersson, and H. Wigzell. 1996. Proliferation of distinct human T cell subsets in response to live, killed or soluble extracts of Mycobacterium tuberculosis and Myco. avium. Clin. Exp. Immunol. 104:419-425.
11. Fine, P. E. 1995. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339-1345.
12. Fine, P. E. M., I. A. M. Carneiro, J. B. Milstien, and J. Clements. 1999. Issues relating to the use of BCG in immunization programmes. Department of Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
13. Gheorghiu, M., and P. H. Lagrange. 1983. Viability, heat stability and immunogenicity of four BCG vaccines prepared from four different BCG strains. Ann. Immunol. (Paris) 134C:125-147.
14. Gobin, J., D. K. Wong, B. W. Gibson, and M. A. Horwitz. 1999. Characterization of exochelins of the Mycobacterium bovis type strain and BCG substrains. Infect. Immun. 67:2035-2039.
15. Gorak-Stolinska, P., R. E. Weir, S. Floyd, M. K. Lalor, S. Stenson, K. Branson, R. Blitz, S. Luke, B. Nazareth, A. Ben-Smith, P. E. Fine, and H. M. Dockrell. 2006. Immunogenicity of Danish-SSI 1331 BCG vaccine in the UK: comparison with Glaxo-Evans 1077 BCG vaccine. Vaccine 24:5726-5733.
16. Grange, J. M., and J. A. Gibson. 1986. Strain to strain variation in the immunogenicity of BCG. Dev. Biol. Stand. 58:37-41.
17. Horwitz, O., and K. Bunch-Christensen. 1972. Correlation between tuberculin sensitivity after 2 months and 5 years among BCG vaccinated subjects. Bull. W. H. O. 47:49-58.
18. Lagranderie, M., A. Balazuc, E. Deriaud, C. Leclerc, and M. Gheorghiu. 1996. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infect. Immun. 64:1-9.
19. Lewinsohn, D. M., M. R. Alderson, A. L. Briden, S. R. Riddell, S. G. Reed, and K. H. Grabstein. 1998. Characterization of human CD8+ T cells reactive with Mycobacterium tuberculosis-infected antigen-presenting cells. J Exp. Med. 187:1633-1640.
20. Li, H., J. C. Ulstrup, T. O. Jonassen, K. Melby, S. Nagai, and M. Harboc. 1993. Evidence for absence of the MPB64 gene in some substrains of Mycobacterium bovis BCG. Infect. Immun. 61:1730-1734.
21. Miura, K., S. Nagai, M. Kinomoto, S. Haga, and T. Tokunaga. 1983. Comparative studies with various substrains of Mycobacterium bovis BCG on the production of an antigenic protein, MPB70. Infect. Immun. 39:540-545.
22. Mostowy, S., A. G. Tsolaki, P. M. Small, and M. A. Behr. 2003. The in vitro evolution of BCG vaccines. Vaccine 21:4270-4274.
23. Smith, S. M., A. S. Malin, T. Pauline, Lukey, S. E. Atkinson, J. Content, K. Huygen, and H. M. Dockrell. 1999. Characterization of human Mycobacterium bovis bacille Calmette-Guerin-reactive CD8+ T cells. Infect. Immun. 67:5223-5230.
24. Turner, J., and H. M. Dockrell. 1996. Stimulation of human peripheral blood mononuclear cells with live Mycobacterium bovis BCG activates cytolytic CD8+ T cells in vitro. Immunology 87:339-342.
25. World Health Organization. 2004. Vaccine-preventable diseases: monitoring system global summary. World Health Organization, Geneva, Switzerland.